Regulatory Considerations for Controlling Intermediates in Type-II Drug Master Files for the Manufacture of Generic Drug Substances

News
Article
Pharmaceutical TechnologyPharmaceutical Technology-03-15-2016
Volume 2016 eBook
Issue 1
Pages: s46-s54

The authors present analysis of the state of control of intermediate identity and quality, based on analysis of recently submitted DMFs.

The authors present analysis of the state of control of intermediate identity and quality, based on analysis of recently submitted DMFs.

Read this article

from Pharmaceutical Technology’s 2016 Solid Dosage Drug Development and Manufacturing eBook.

View other articles in the

2016 Solid Dosage Drug Development and Manufacturing eBook.
Articles in this issue
Meeting USP Guidelines for Elemental Impurity Analysis with X-ray Fluorescence Spectrometry
Meeting USP Guidelines for Elemental Impurity Analysis with X-ray Fluorescence Spectrometry
Optimizing Tablet Compression
Optimizing Tablet Compression
Excipient-Quality-and-Selection.jpg
Excipient Quality and Selection
Pages-from-PTeBook0316_034-038_continuous_freeman.jpg
Filling the Analysis Gap in the Move to Continuous Processing
Pages-from-PTeBook0316_046-054_Generics_DMFs_Subburaj.jpg
Regulatory Considerations for Controlling Intermediates in Type-II Drug Master Files for the Manufacture of Generic Drug Substances
Pages-from-PTEBook0316_022-025_Modeling.jpg
Modeling and Simulation Move Downstream
Unifying-Excipient-Databases.jpg
Unifying Excipient Databases
Pages-from-PTeBook0316_020-021_Capsugel.jpg
Establishing a New Performance Standard for HPMC Capsules
Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Related Content
Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – © Dilok - stock.adobe.com

Shilpa Biologicals and mAbTree Biologics to Collaborate on Novel Immuno-Oncology Asset

Feliza Mirasol
March 18th 2025
Article

The partnership aims to develop and commercialize a novel checkpoint inhibitor for immuno-oncology applications.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency

Patrick Lavery
March 14th 2025
Article

The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Magnified View of Lipid Nanoparticles | Image Credit: ©Aniwat - stock.adobe.com

Organic Nanoparticle-Based Drug-Delivery Systems as Alternatives to Lipid Nanoparticles

Cynthia A. Challener
March 9th 2025
Article

Exosomes, polymeric nanoparticles, and DNA nanostructures offer many potential advantages.

Isometric View of a Pharmaceutical Factory - Industrial Design for Prints, Cards, Posters, and Digital Graphics | Image Credit: © Anna– Stock.Adobe.com

Design Quality in Pharmaceutical Design: A Primer for Facility Executives

Aimee Penko
March 7th 2025
Article

Being fully versed on the ins and outs of design quality can improve the project design phase life cycle.